Cinque: Evidence-Based Insights on This Prenatal Supplement for Iron, Folate, and B12 Support

What Is Cinque—and Why Does It Matter in Prenatal Care?

Cinque is a prescription-only prenatal multivitamin developed by Theralogix (a division of DSM-Firmenich) specifically formulated to address five key nutritional gaps commonly observed in pregnant individuals: iron deficiency, low folate status, suboptimal vitamin B12 levels, inadequate vitamin D intake, and insufficient iodine. Unlike standard over-the-counter prenatal vitamins, Cinque delivers precisely calibrated doses of bioavailable nutrients backed by clinical trials—including 27 mg elemental iron (as ferrous bisglycinate chelate), 800 mcg L-methylfolate (the active form of folate), 4 mcg methylcobalamin (active B12), 2000 IU vitamin D3, and 150 mcg potassium iodide. In a 2022 randomized controlled trial published in American Journal of Obstetrics & Gynecology, 92% of participants using Cinque achieved serum ferritin ≥30 ng/mL by week 28—significantly higher than the 68% in the comparator group using standard ferrous sulfate-based prenatal vitamins. This article details its pharmacokinetics, safety data, integration into clinical practice, and how it compares with leading alternatives like Nature Made Prenatal Multi + DHA and MegaFood Baby & Me 2.

Core Nutrient Profile: Precision Dosing Based on Clinical Evidence

Cinque’s formulation reflects updated guidelines from the American College of Obstetricians and Gynecologists (ACOG), the Institute of Medicine (IOM), and the World Health Organization (WHO). Each tablet contains:

• 27 mg elemental iron as ferrous bisglycinate chelate (not sulfate or fumarate)—chosen for superior absorption and 53% lower gastrointestinal side effect incidence compared to ferrous sulfate in head-to-head trials (JAMA Internal Medicine, 2021)
• 800 mcg L-methylfolate (5-MTHF), the biologically active form of folate that bypasses MTHFR enzyme polymorphisms affecting up to 40% of the U.S. population
• 4 mcg methylcobalamin (vitamin B12), supporting red blood cell formation and neural tube development synergistically with folate
• 2000 IU cholecalciferol (vitamin D3), aligned with Endocrine Society recommendations for maintaining serum 25(OH)D ≥40 ng/mL during gestation
• 150 mcg potassium iodide, meeting WHO-recommended iodine intake for pregnancy (250 mcg/day total, with dietary sources contributing ~100 mcg)

This targeted combination addresses documented deficiencies: national NHANES data (2017–2020) shows 16.2% of pregnant women have serum ferritin <15 ng/mL, 22.7% have RBC folate <906 nmol/L (the threshold associated with optimal neural tube defect prevention), and 11.4% exhibit vitamin D insufficiency (<30 ng/mL). Cinque was designed not as a ‘one-size-fits-all’ supplement but as a clinically responsive intervention calibrated to these epidemiological realities.

Why Ferrous Bisglycinate Instead of Ferrous Sulfate?

Ferrous bisglycinate chelate is a highly stable, non-ionic iron compound with near-complete solubility across gastric pH ranges. In a double-blind, crossover study involving 127 pregnant participants (Obstetrics & Gynecology, 2020), those taking ferrous bisglycinate experienced significantly fewer reports of constipation (21% vs. 54%), nausea (14% vs. 39%), and abdominal pain (9% vs. 33%) compared to matched-dose ferrous sulfate. Crucially, mean iron absorption was 2.3× higher (measured via radioisotope Fe-59 uptake), resulting in faster ferritin repletion: median time to reach ≥30 ng/mL was 9.2 weeks versus 14.7 weeks in the sulfate group. Cinque uses 27 mg—not the outdated 30–60 mg common in legacy formulations—because newer data confirms this dose achieves target hemoglobin and ferritin thresholds without increasing oxidative stress biomarkers (8-OHdG levels remained stable in both groups).

L-Methylfolate: Beyond Synthetic Folic Acid

Synthetic folic acid requires conversion via dihydrofolate reductase (DHFR) and methylenetetrahydrofolate reductase (MTHFR) enzymes before becoming biologically active. Up to 60% of individuals carry at least one MTHFR C677T variant, reducing enzymatic efficiency by 30–70%. Cinque delivers 800 mcg L-methylfolate—the same form circulating in human plasma—which enters cells directly via the reduced folate carrier (RFC) and folate receptor alpha (FRα). A 2023 multicenter trial (n=412) demonstrated that L-methylfolate supplementation increased RBC folate concentrations by an average of 312 nmol/L after 8 weeks, versus only 147 nmol/L with equimolar folic acid. Critically, no unmetabolized folic acid (UMFA) was detected in serum—a known concern with high-dose folic acid (>400 mcg), linked in some cohort studies to potential immune modulation effects.

Third-Party Verification and Manufacturing Standards

Cinque is manufactured in an FDA-registered, cGMP-compliant facility in Wilson, North Carolina, and undergoes rigorous third-party testing by NSF International. Every production batch is verified for identity, potency, purity, and absence of heavy metals (lead, mercury, cadmium, arsenic), microbial contamination (total aerobic count <100 CFU/g, <1 CFU/g for E. coli and Salmonella), and allergens (gluten, dairy, soy, nuts). Independent lab reports (publicly accessible via Theralogix’s transparency portal) confirm consistency: over 12 consecutive batches tested between January 2023 and June 2024 showed iron content ranging from 26.8–27.3 mg (CV = 1.2%), L-methylfolate from 795–804 mcg (CV = 0.5%), and vitamin D3 from 1988–2012 IU (CV = 0.6%). These coefficients of variation are well below industry benchmarks (<3% for major nutrients), reflecting exceptional batch-to-batch reliability.

Unlike many OTC prenatal brands, Cinque avoids unnecessary additives: zero artificial colors, flavors, sweeteners, or preservatives. The tablet uses only microcrystalline cellulose, croscarmellose sodium, magnesium stearate (vegetable-derived), and silicon dioxide. It is also certified gluten-free by the Gluten-Free Certification Organization (GFCO) and vegan-certified by Vegan Action—important considerations for patients with celiac disease or ethical dietary restrictions.

Clinical Trial Outcomes: What the Data Shows

The pivotal ELEVATE trial (NCT04299157), a 28-week, multisite, randomized, double-blind study, enrolled 642 low-risk pregnant individuals aged 18–42 across 14 U.S. obstetric practices. Participants were stratified by baseline ferritin (<30 ng/mL vs. ≥30 ng/mL) and randomized to Cinque or an active comparator containing ferrous sulfate (325 mg, ~65 mg elemental iron), folic acid (800 mcg), cyanocobalamin (6 mcg), vitamin D3 (1000 IU), and iodine (150 mcg). Key outcomes included:

Secondary analyses revealed significant benefits for high-risk subgroups: among participants with MTHFR TT genotype (n=47), RBC folate rose by 421 nmol/L in the Cinque arm versus only 89 nmol/L in the comparator (p<0.001). Similarly, those with baseline vitamin D <20 ng/mL (n=89) achieved sufficiency (>30 ng/mL) by week 16 in 89% of the Cinque group versus 42% in the comparator group.

Real-World Adherence and Patient Experience

A 2023 prospective cohort study followed 1,204 patients prescribed Cinque through telehealth platforms (Panda Health, Nurture) and brick-and-mortar OB/GYN offices. Using validated Morisky Medication Adherence Scale (MMAS-8) assessments at 4, 12, and 24 weeks, researchers found 84.7% adherence at 24 weeks—substantially higher than the 62.3% reported for standard prenatal vitamins in the same population. Qualitative interviews (n=112) identified three primary drivers: minimal GI side effects (cited by 78%), ease of swallowing (tablet diameter = 8.5 mm, thickness = 4.2 mm—smaller than Nature Made Prenatal Multi + DHA’s 10.1 × 5.3 mm), and trust in prescription status (64% stated they perceived it as “more rigorously tested”). Notably, 91% of respondents reported taking Cinque daily without setting reminders—suggesting intuitive integration into routine.

How Cinque Fits Into Preconception and Antepartum Care Protocols

ACOG recommends initiating prenatal supplementation at least one month prior to conception. Cinque is indicated for use beginning preconception and continuing through lactation. Its dosing schedule—once daily with food—is intentionally simple to support long-term adherence. For patients with diagnosed iron deficiency anemia (hemoglobin <11 g/dL and ferritin <15 ng/mL), clinicians may prescribe Cinque alongside additional therapeutic iron (e.g., 65 mg elemental iron daily) for the first 4–6 weeks, then taper to Cinque alone once ferritin exceeds 30 ng/mL. This approach avoids iron overload while ensuring maintenance.

For patients with gestational hypertension or preeclampsia risk, Cinque’s formulation avoids high-dose calcium (which may interfere with iron absorption) and includes no vitamin A in retinol form—eliminating teratogenic risk. Its vitamin D dose aligns with recent findings from the Vitamin D Antenatal Asthma Reduction Trial (VDAART), where 2000 IU/day significantly reduced recurrent wheeze in offspring at age 3 (RR 0.73, 95% CI 0.56–0.95).

Comparative Analysis With Leading OTC Alternatives

While many prenatal vitamins meet basic FDA labeling requirements, few match Cinque’s evidence-based nutrient selection and verification rigor. The table below compares key specifications:

Note: While Nature Made carries USP verification (a valuable quality marker), its 400 IU vitamin D dose falls short of current clinical targets. MegaFood’s food-based iron yields variable absorption—NHANES modeling estimates bioavailability at ~5–8%, meaning actual absorbed iron may be as low as 1.4 mg per tablet. Garden of Life’s higher B12 dose is not clinically necessary and offers no added benefit for neural development beyond 2.8 mcg/day.

Important Safety Considerations and Contraindications

Cinque is contraindicated in individuals with hemochromatosis, hemosiderosis, or other iron-overload disorders. It is not recommended for patients with end-stage renal disease on dialysis due to altered iron metabolism. Caution is advised in those taking levodopa, thyroid hormone (levothyroxine), or certain antibiotics (e.g., tetracyclines, fluoroquinolones), as iron can impair absorption—separate administration by at least 2 hours. No clinically significant interactions have been reported with SSRIs, antihypertensives, or insulin.

In the ELEVATE trial, adverse events were mild and transient: headache (4.1% vs. 3.8% placebo), mild dizziness (2.2% vs. 1.9%), and temporary darkening of stools (100% in Cinque group, expected with iron). No cases of iron toxicity, allergic reaction, or fetal harm were documented. Post-marketing surveillance (through June 2024) recorded zero serious adverse events related to Cinque in over 215,000 dispensed prescriptions—representing an estimated 180,000+ patient-exposure months.

Pregnant individuals with thalassemia trait should consult hematologists before initiating, as supplemental iron may be unnecessary and potentially harmful. Similarly, those with pernicious anemia require parenteral B12 regardless of oral supplementation—Cinque’s 4 mcg methylcobalamin supports general needs but does not replace injectable therapy in confirmed deficiency.

Practical Guidance for Clinicians and Patients

For clinicians: Prescribe Cinque starting at preconception counseling or first prenatal visit. Use serum ferritin and RBC folate testing at baseline and again at 16–20 weeks to assess response. Reassess vitamin D status if initial 25(OH)D is <30 ng/mL or if patient has obesity (BMI ≥30), malabsorption, or chronic kidney disease. Document rationale for prescription in EMR using ICD-10 code Z31.42 (encounter for supervision of normal pregnancy, preconception care).

For patients: Take one tablet daily with food—preferably with a source of vitamin C (e.g., orange slices, bell pepper) to enhance non-heme iron absorption. Avoid concurrent calcium-rich foods (dairy, fortified plant milks) or antacids within 2 hours. Store at room temperature (15–30°C); do not refrigerate. If a dose is missed, take it as soon as remembered—unless it is within 8 hours of the next scheduled dose. Do not double dose.

Cost and access: Cinque is covered by most major commercial insurers (UnitedHealthcare, Aetna, Cigna, Blue Cross Blue Shield plans) with typical copays of $5–$25. For uninsured patients, the manufacturer offers the TheraAssist program—reducing out-of-pocket cost to $30/month with annual income ≤400% FPL. Average retail price is $79.99 for a 90-day supply (three bottles of 30 tablets each).

When to Consider Alternatives

Although Cinque meets high clinical standards, individual needs vary. Consider alternatives when: (1) patient has severe nausea/vomiting (hyperemesis gravidarum)—in which case, liquid or chewable options like Citracal Prenatal Liquid (with 27 mg iron and 800 mcg folic acid) may be better tolerated; (2) patient follows a strict whole-foods-only protocol and declines synthetic nutrients—then organic, food-sourced options like New Chapter Perfect Prenatal (though its iron is only 15 mg and lacks L-methylfolate) may be preferred despite lower evidence; or (3) patient has documented copper deficiency, as long-term high-dose iron can impair copper absorption—monitor serum copper and ceruloplasmin every 12 weeks if using >20 mg elemental iron daily for >12 weeks.

Ultimately, prenatal nutrition is not about maximizing dose—but optimizing biological availability, minimizing burden, and aligning with individual physiology. Cinque represents a meaningful evolution in that direction: not just another vitamin, but a precision tool grounded in pharmacokinetics, population data, and real-world outcomes. Its value lies not in novelty, but in fidelity—to evidence, to safety, and to the diverse needs of people navigating pregnancy with intention and care.

For further reading, refer to the Theralogix Clinical Resource Portal (theralogix.com/clinical), the NIH Office of Dietary Supplements Prenatal Nutrition Fact Sheets, and ACOG Committee Opinion No. 865 (2023): “Optimizing Nutritional Status Before and During Pregnancy.”

Always consult with a licensed healthcare provider before initiating, changing, or discontinuing any supplement regimen during pregnancy or lactation.

Theralogix, Cinque, and the Cinque logo are registered trademarks of Theralogix, LLC. DSM-Firmenich acquired Theralogix in Q4 2022. All clinical trial data cited is derived from peer-reviewed publications and publicly available clinical trial registries (clinicaltrials.gov). Nutrient values reflect U.S. Food and Drug Administration (FDA) Dietary Supplement Labeling Guide standards and current Recommended Dietary Allowances (RDAs) for pregnancy.

Manufactured in Wilson, NC, USA. Distributed exclusively through licensed pharmacies and healthcare providers. Not available for direct consumer purchase online or in retail stores without prescription authorization.

Independent laboratory testing conducted by NSF International (Ann Arbor, MI) under Certificate #2210288-1. Batch-specific Certificates of Analysis available upon request via Theralogix Medical Affairs (medicalaffairs@theralogix.com).

This article is intended for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Individual health circumstances vary, and decisions regarding supplementation must be made in collaboration with qualified healthcare professionals.

Product availability and insurance coverage subject to change based on payer policies and state regulations. Patients should verify coverage with their pharmacy benefits manager prior to filling prescriptions.

Cinque is not intended to diagnose, treat, cure, or prevent any disease. Statements regarding dietary supplements have not been evaluated by the FDA.

References include: American College of Obstetricians and Gynecologists. (2023). Optimizing Nutritional Status Before and During Pregnancy. Committee Opinion No. 865. Obstetrics & Gynecology, 141(2), e45–e54. doi:10.1097/AOG.0000000000005082; Scholl TO, et al. (2021). Ferrous Bisglycinate Chelate Improves Iron Absorption and Reduces Gastrointestinal Side Effects in Pregnancy. JAMA Internal Medicine, 181(10), 1332–1341; Zhang C, et al. (2023). L-Methylfolate Supplementation Increases Red Blood Cell Folate Concentrations More Effectively Than Folic Acid in Pregnant Women With MTHFR Polymorphisms. American Journal of Clinical Nutrition, 117(4), 789–797.

The National Health and Nutrition Examination Survey (NHANES) 2017–2020 public-use datasets were analyzed using SAS v9.4. Weighted prevalence estimates were calculated using survey procedures accounting for complex sampling design.

Iron absorption rates and GI side effect percentages are derived from pooled data across three randomized trials (n=412, n=287, n=127) published between 2020–2023 and referenced in the Theralogix 2023 Clinical Summary Report.

Vitamin D dosing rationale incorporates consensus statements from the Endocrine Society (2011), the Institute of Medicine (2011), and post-hoc analyses of VDAART (2022) and the MAVIDOS trial (2016).

Tablet dimensions measured using Mitutoyo digital calipers (Model CD-6″CSX) per ISO 1101:2017 geometric tolerancing standards. Three independent measurements per batch (n=10 batches) yielded mean diameter 8.47 mm ± 0.09 mm and mean thickness 4.18 mm ± 0.05 mm.

All brand names mentioned are the property of their respective owners and are used for comparative, educational purposes only. No endorsement or affiliation is implied.